Biointerfacing Antagonizing T‐Cell Inhibitory Nanoparticles Potentiate Hepatocellular Carcinoma Checkpoint Blockade Therapy (Small 51/2021)
Han Wu(Peking University), Tian Yang(Second Military Medical University), Feng Shen(Second Military Medical University), Hao Xing(The Graduate Center, CUNY), Ming‐Da Wang(Second Military Medical University), Xin‐Fei Xu(Second Military Medical University), Jiaqi Zhu(Zhejiang Provincial People's Hospital), Chao Li(Eli Lilly (United States)), Hang‐Dong Jia(Zhejiang Provincial People's Hospital), Dong‐Sheng Huang(Zhejiang Provincial People's Hospital), Lei Liang(Zhejiang Provincial People's Hospital)
Cited by 3
Related Papers
Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma
|JAMA Surgery|2018|546
microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity
|British Journal of Cancer|2010|252
Dioscin Alleviates Crystalline Silica-Induced Pulmonary Inflammation and Fibrosis through Promoting Alveolar Macrophage Autophagy
|Theranostics|2019|242
Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma
|Annals of Surgery|2018|230